Faculty of Pharmacy, Department of Pharmaceutical Sciences, Universitas Airlangga, Surabaya, Indonesia.
J Basic Clin Physiol Pharmacol. 2021 Jun 25;32(4):623-630. doi: 10.1515/jbcpp-2020-0456.
Loratadine belongs to Class II compound of biopharmaceutics classification system (BCS) due its low solubility and high membrane permeability. Cocrystal is a system of multicomponent crystalline that mostly employed to improve solubility. Succinic acid is one of common coformer in cocrystal modification. This research aims to investigate cocrystal formation between loratadine and succinic acid and its effect on solubility property of loratadine.
Cocrystal of loratadine-succinic acid was prepared by solution method using methanol as the solvent. Cocrystal formation was identified under observation of polarization microscope and analysis of the binary phase diagram. The cocrystal phase was characterized by differential thermal analysis (DTA), powder X-ray diffraction (PXRD), Fourier transform infrared (FTIR), and scanning electron microscopy (SEM). Solubility study was conducted in phosphate-citrate buffer pH 7.0 ± 0.5 at 30 ± 0.5 °C.
Loratadine is known to form cocrystal with succinic acid in 1:1 M ratio. Cocrystal phase has lower melting point at 110.9 °C. Powder diffractograms exhibited new diffraction peaks at 2 of 5.28, 10.09, 12.06, 15.74, 21.89, and 28.59° for cocrystal phase. IR spectra showed that there was a shift in C=O and O-H vibration, indicating intermolecular hydrogen bond between loratadine and succinic acid. SEM microphotographs showed different morphology for cocrystal phase. Loratadine solubility in cocrystal phase was increased up to 2-fold compared to loratadine alone.
Cocrystal of loratadine and succinic acid is formed by stoichiometry of 1:1 via C=O and H-O interaction. Cocrystal phase shows different physicochemical properties and responding to those properties, it shows improved loratadine solubility as well.
氯雷他定属于生物药剂学分类系统(BCS)的 II 类化合物,因其低溶解度和高膜透过性。共晶是一种多组分晶体系统,主要用于提高溶解度。琥珀酸是共晶改性中常用的共晶形成剂之一。本研究旨在研究氯雷他定与琥珀酸形成共晶及其对氯雷他定溶解度性质的影响。
采用甲醇为溶剂的溶液法制备氯雷他定-琥珀酸共晶。通过偏光显微镜观察和二元相图分析来鉴定共晶的形成。采用差示热分析(DTA)、粉末 X 射线衍射(PXRD)、傅里叶变换红外(FTIR)和扫描电子显微镜(SEM)对共晶相进行表征。在磷酸盐-柠檬酸盐缓冲液 pH7.0±0.5 下于 30±0.5°C 进行溶解度研究。
已知氯雷他定与琥珀酸以 1:1 的摩尔比形成共晶。共晶相的熔点较低,为 110.9°C。粉末衍射图在 2θ 为 5.28、10.09、12.06、15.74、21.89 和 28.59°处出现新的衍射峰,表明共晶相的形成。IR 光谱显示 C=O 和 O-H 振动发生位移,表明氯雷他定与琥珀酸之间存在分子间氢键。SEM 显微照片显示共晶相的形貌不同。与单独的氯雷他定相比,共晶相的氯雷他定溶解度提高了 2 倍。
氯雷他定和琥珀酸通过 C=O 和 H-O 相互作用以 1:1 的化学计量比形成共晶。共晶相表现出不同的物理化学性质,并且对这些性质有响应,因此也表现出改善的氯雷他定溶解度。